Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings [Yahoo! Finance]
Pyxis Oncology, Inc. (PYXS)
Company Research
Source: Yahoo! Finance
MICVO combats solid tumors through three-pronged mechanism of action: direct tumor cell killing, bystander effect, and immunogenic cell death Findings demonstrate MICVO's effects on tumor microenvironment remodeling and immune activation Translational data to be presented in two posters at ESMO 2025 and six posters at AACR-NCI-EORTC BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, announced today that it will present translational data for micvotabart pelidotin (MICVO), a first-in-concept antibody-drug conjugate (ADC) that cleaves in the extracellular matrix and targets extradomain-B of fibronectin (EDB+FN), at upcoming medical meetings. Data will be presented at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany (October 17-21, 2025), and at the AACR-NCI-EORTC International Conference in Boston, Massachusetts (October 22-
Show less
Read more
Impact Snapshot
Event Time:
PYXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PYXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PYXS alerts
High impacting Pyxis Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
PYXS
News
- Pyxis Oncology (NASDAQ:PYXS) had its "overweight" rating reaffirmed by analysts at Stephens.MarketBeat
- Pyxis Oncology (NASDAQ:PYXS) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- Pyxis Oncology (NASDAQ:PYXS) was given a new $7.00 price target on by analysts at Guggenheim.MarketBeat
- Pyxis Oncology to Participate in Upcoming Investor ConferencesGlobeNewswire
- Pyxis Oncology (NASDAQ:PYXS) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $9.00 price target on the stock.MarketBeat
PYXS
Earnings
- 8/14/25 - Beat
PYXS
Sec Filings
- 11/26/25 - Form S-3
- 11/3/25 - Form 10-Q
- 11/3/25 - Form 8-K
- PYXS's page on the SEC website